Neurocognitive Disorders Clinical Trial
Official title:
Contribution of Brain Positon Emission Tomography With 18 Flurodeoxyglucose Labelled With Fluorine 18 for the Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin
The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.
Neurocognitive disorder or Mild Cognitive Impairment corresponds to a decline in one or more cognitive functions; compared to the previous level of performance. Indeed, the prevalence of neurodegenerative pathologies is estimated at more than one million according to Santé Publique France, due to the aging of the population. To be compared with the prevalence of the population suffering from a psychiatric disorder estimated at one in five people, or 13 million French people, in 2021. With the increase in the prevalence of these two entities and their clinical entanglement, the question arises of the origin of neurocognitive disorders, is it a manifestation of a psychiatric pathology or a neurodegenerative pathology not yet diagnosed. If this is the case, the patient's prognosis is modified with a pejorative evolution and a loss of autonomy which is to be anticipated. This delay deprives the patient and his family of interventions likely to alleviate behavioral disorders; maintain a level of autonomy compatible with life at home; alleviates the burden and improves the quality of life of caregivers. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05754567 -
CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes
|
||
| Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
| Not yet recruiting |
NCT03276377 -
VItamin K Inhibition and NeurocoGnition (VIKING)
|
N/A | |
| Completed |
NCT04175223 -
Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders
|
N/A | |
| Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
| Recruiting |
NCT05732285 -
A Pilot Randomized Controlled Trial: CoINTEGRATE
|
N/A | |
| Recruiting |
NCT04095962 -
Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia
|
N/A | |
| Not yet recruiting |
NCT04113577 -
COgilus Remediation in Alzheimer Patients (CORA)
|
||
| Recruiting |
NCT06320639 -
DRIVing Simulator and People With NeuroCognitive Disorders
|
||
| Recruiting |
NCT06105320 -
COGNIFOOD-Changing the Carbohydrate/Fat-ratio to Prevent Cognitive Decline and Alzheimer Pathology: A Pilot Study
|
N/A | |
| Completed |
NCT03050385 -
Cognitive Rehabilitation During Transcranial Direct Current Stimulation
|
N/A | |
| Active, not recruiting |
NCT06372002 -
Effectiveness and Cost-Effectiveness of Cognitive Stimulation Therapy - Spain (CST-ES) in People Living With Dementia
|
N/A | |
| Recruiting |
NCT05508789 -
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
|
Phase 3 | |
| Recruiting |
NCT03926351 -
High Dose Omega 3 in People at Risk for Dementia
|
Phase 2 | |
| Recruiting |
NCT05504681 -
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
|
||
| Completed |
NCT04168268 -
Patient-reported Outcome Measures After Post-anesthesia Care Unit Delirium
|
||
| Recruiting |
NCT04825847 -
Neurocognitive Disorders After Major Surgery in Elderly
|
N/A | |
| Active, not recruiting |
NCT02958670 -
Imaging Tau Deposition in the Brain of Elderly Subjects
|
N/A | |
| Enrolling by invitation |
NCT02652598 -
Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD
|
Phase 2 | |
| Completed |
NCT02825732 -
MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint
|
N/A |